<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5403">
  <stage>Registered</stage>
  <submitdate>7/08/2015</submitdate>
  <approvaldate>7/08/2015</approvaldate>
  <nctid>NCT02520284</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy of GS-5745 in Adults With Moderately to Severely Active Ulcerative Colitis</studytitle>
    <scientifictitle>A Combined Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Induction and Maintenance Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Ulcerative Colitis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2014-005217-24</secondaryid>
    <secondaryid>GS-US-326-1100</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Ulcerative Colitis</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Inflammatory bowel disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - GS-5745
Other interventions - Placebo

Experimental: GS-5745 weekly (Cohort 1) - Participants will receive GS-5745 weekly doses for 8 weeks. Based on Week 8 assessment results, participants will either continue on blinded treatment or will be offered open-label GS-5745 weekly.

Experimental: GS-5745 every 2 weeks (Cohort 1) - Participants will receive weekly GS-5745 doses alternating with placebo for 8 weeks. Based on Week 8 assessment results, participants will either continue on blinded treatment or will be offered open-label GS-5745 weekly.

Placebo Comparator: Placebo (Cohort 1) - Participants will receive GS-5745 placebo weekly for 8 weeks. Based on Week 8 assessment results, participants will either continue on blinded treatment or will be offered open-label GS-5745 weekly.

Experimental: GS-5745 (Cohort 2) - Participants will receive open-label GS-5745 at the optimal regimen (based on Cohort 1 data analysis) for the first 8 weeks, followed by blinded GS-5745 weekly or every 2 weeks (whichever is determined to be the optimal regimen) for a total of 43 doses.

Experimental: GS-5745 every 2 weeks (Cohort 2) - Participants will receive open-label GS-5745 at the optimal regimen (based on Cohort 1 data analysis) for the first 8 weeks, followed by weekly GS-5745 doses alternating with placebo for a total dose of 21 active GS-5745 doses. Note this treatment group will only be initiated if the optimal dosing regimen is determined to be weekly.

Placebo Comparator: Placebo (Cohort 2) - Participants will receive open-label GS-5745 at the optimal regimen (based on Cohort 1 data analysis) for the first 8 weeks, followed by GS-5745 placebo weekly or every 2 weeks (whichever is determined to be the optimal regimen).

Experimental: Extended Treatment Phase - All participants that complete 52 weeks of treatment (in either Cohorts 1 or 2) will have the option to enter the Extended Treatment Phase to receive open-label GS-5745 weekly.


Other interventions: GS-5745
GS-5745 150 mg administered subcutaneously

Other interventions: Placebo
GS-5745 placebo administered subcutaneously

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>For Cohort 1, proportion of participants achieving remission at Week 8 based on select mayo clinical score (MCS) measures</outcome>
      <timepoint>Week 8</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>For Cohort 2, proportion of participants achieving remission at Week 52 based on select MCS measures</outcome>
      <timepoint>Week 52</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>For Cohort 1, proportion of participants achieving MCS remission at Week 8</outcome>
      <timepoint>Week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>For Cohort 1, proportion of participants achieving MCS response at Week 8</outcome>
      <timepoint>Week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>For Cohort 1, proportion of participants achieving sustained clinical remission at Week 52 based on select MCS measures - The sustained clinical remission is defined as achieving clinical remission at both Week 8 and Week 52 based on select MCS measures.</outcome>
      <timepoint>Weeks 8 and 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>For Cohort 1, proportion of participants achieving endoscopic remission at Week 8</outcome>
      <timepoint>Week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>For Cohort 1, proportion of participants achieving endoscopic response at Week 8</outcome>
      <timepoint>Week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>For Cohort 1, proportion of participants achieving mucosal healing as determined by histologic measures at Week 8</outcome>
      <timepoint>Week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>For Cohort 1, proportion of participants achieving remission as defined by MCS remission (alternative definition) at Week 8</outcome>
      <timepoint>Week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>For Cohort 2, proportion of participants achieving MCS remission at Week 52</outcome>
      <timepoint>Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>For Cohort 2, proportion of participants achieving corticosteroid-free clinical remission at Week 52 based on select MCS measures</outcome>
      <timepoint>Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>For Cohort 2, proportion of participants achieving endoscopic remission at Week 52</outcome>
      <timepoint>Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>For Cohort 2, proportion of participants achieving mucosal healing as determined by histologic measures at Week 52</outcome>
      <timepoint>Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>For Cohort 2, proportion of participants achieving remission as defined by MCS remission (alternative definition) at Week 52</outcome>
      <timepoint>Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>For Cohort 2, proportion of participants achieving corticosteroid-free clinical remission for at least 24 weeks prior to Week 52</outcome>
      <timepoint>Up to 52 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  Ulcerative Colitis (UC) confirmed on endoscopy

          -  Moderately to severely active UC (Mayo Score 6-12)

          -  May be receiving oral 5-aminosalicylate (ASA), oral corticosteroid, Azathioprine,
             6-mercaptopurine(MP), or methotrexate

          -  Treatment failure with at least one of the following agents received; Corticosteroids,
             Immunomodulators, tumor necrosis factor-alpha (TNFa) Antagonists, Vedolizumab

        Key</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Diagnose of Crohn's disease or indeterminate colitis

          -  Pregnant or lactating females

          -  Any chronic medical condition (including, but not limited to cardiac or pulmonary
             disease, alcohol or drug abuse)

          -  Exhibit severe UC / clinically significant active infection

          -  History of malignancy in the last 5 years

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2/Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>165</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Footscray</hospital>
    <hospital> - Herston</hospital>
    <hospital> - Malvern</hospital>
    <hospital> - Melbourne</hospital>
    <postcode> - Footscray</postcode>
    <postcode> - Herston</postcode>
    <postcode> - Malvern</postcode>
    <postcode> - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Mouscron</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Pleven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Hradec Kralove</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Bekescsaba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Leinster</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rozzano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>San Giovanni Rotondo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Suwon-si</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Daugavpils</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Canterbury Region</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bialystok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Piaseczno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Sopot</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Sroda Wielkopolska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Tychy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucharest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Timisoara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Novosibirsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Rostov-on-Don</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint-Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Trencin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Western Cape</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Basel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Bern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taichung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kharkov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kyiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Lviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Odessa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Vinnitsa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cambridge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Oxford</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Prescot</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Gilead Sciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will evaluate the efficacy, safety, and tolerability of GS-5745. It will consist
      of 3 parts: Induction Study (Cohort 1), and Maintenance Study (Cohort 2), and an Extended
      Treatment Phase.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02520284</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gilead Study Director</name>
      <address>Gilead Sciences</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>